Wixela Inhub Diskus 250/50mcg 60s

Manufacturer MYLAN Active Ingredient Fluticasone and Salmeterol Inhalation Powder(floo TIK a sone & sal ME te role) Pronunciation floo TIK a sone & sal ME te role
It is used to treat asthma.Some brands are used to treat COPD (chronic obstructive pulmonary disease).It may be given to you for other reasons. Talk with the doctor.Do not use this drug to treat intense flare-ups of shortness of breath. Use a rescue inhaler. If you have questions, talk with the doctor.
🏷️
Drug Class
Bronchodilator/Corticosteroid Combination
🧬
Pharmacologic Class
Inhaled Corticosteroid (ICS) / Long-Acting Beta2-Adrenergic Agonist (LABA)
🀰
Pregnancy Category
Category C
βœ…
FDA Approved
Jan 2019
βš–οΈ
DEA Schedule
Not Controlled

Overview

ℹ️

What is this medicine?

Wixela Inhub is an inhaler that contains two medicines: fluticasone and salmeterol. Fluticasone is a steroid that helps reduce inflammation in your lungs, making it easier to breathe. Salmeterol is a long-acting bronchodilator that helps open up your airways for about 12 hours. This medicine is used twice a day to help prevent asthma attacks or to manage COPD symptoms. It is not for sudden breathing problems.
πŸ“‹

How to Use This Medicine

Proper Use of This Medication

To use this medication correctly, follow your doctor's instructions and read all the information provided. This medication is for inhalation only. Continue using it as directed by your doctor or healthcare provider, even if you feel well. Take your dose at the same time every day.

After each use, rinse your mouth with water, but do not swallow the water. Instead, spit it out. If you are using multiple inhaled medications, consult your doctor about which one to use first.

Preparing and Taking Your Dose

Only prepare a dose when you are ready to take it. If you prepare a dose and then close the inhaler without taking it, the medication will be wasted and the inhaler may be damaged. When taking your dose, do not breathe out into the inhaler. Close the inhaler after use.

Important Safety Precautions

Do not take an extra dose, even if you did not taste or feel the powder. Do not disassemble the device or wash it, and do not use it with a spacer. Also, avoid breathing out into the device.

Cleaning and Maintenance

To clean the mouthpiece, gently wipe it with a dry tissue or cloth. Do not wash the mouthpiece or submerge it in water.

Tracking Your Doses

The inhaler has a built-in dose counter to help you keep track of how many doses are left. Once the counter reaches "0," or after 1 month from opening the foil pouch, or when the expiration date is reached (whichever comes first), discard the inhaler.

Storage and Disposal

Store the medication at room temperature in a dry place, avoiding bathrooms. Keep it in the foil pouch until you are ready to use it.

What to Do If You Miss a Dose

If you miss a dose, skip it and return to your regular schedule. Do not take two doses at the same time or take extra doses.
πŸ’‘

Lifestyle & Tips

  • Use the inhaler exactly as prescribed, usually twice a day, about 12 hours apart. Do not use more often or at higher doses.
  • This medicine is for prevention and maintenance; it is NOT a rescue inhaler for sudden breathing problems. Always carry your fast-acting rescue inhaler (e.g., albuterol) for acute symptoms.
  • Rinse your mouth with water and spit it out after each dose to help prevent oral thrush (a fungal infection in the mouth). Do not swallow the water.
  • Do not stop using this medicine suddenly, even if you feel better, without talking to your doctor.
  • Keep track of your asthma/COPD symptoms and how often you use your rescue inhaler. Report any worsening symptoms to your doctor.
  • Avoid triggers that worsen your asthma/COPD (e.g., smoke, allergens, pollution).
  • Ensure proper inhaler technique. Your pharmacist or doctor can demonstrate how to use the Diskus device correctly.

Dosing & Administration

πŸ‘¨β€βš•οΈ

Adult Dosing

Standard Dose: One inhalation (250 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart.

Condition-Specific Dosing:

asthma: One inhalation (250/50 mcg) twice daily.
COPD: One inhalation (250/50 mcg) twice daily.
πŸ‘Ά

Pediatric Dosing

Neonatal: Not established
Infant: Not established
Child: Not established for this strength (Wixela Inhub is approved for 12 years and older for asthma). For asthma in children 4-11 years, lower strengths of fluticasone/salmeterol (e.g., 100/50 mcg) may be used.
Adolescent: For asthma (12 years and older): One inhalation (250/50 mcg) twice daily.
βš•οΈ

Dose Adjustments

Renal Impairment:

Mild: No dosage adjustment necessary.
Moderate: No dosage adjustment necessary.
Severe: No dosage adjustment necessary.
Dialysis: No specific recommendations; systemic exposure is low.

Hepatic Impairment:

Mild: No dosage adjustment necessary.
Moderate: Use with caution; monitor for systemic corticosteroid effects.
Severe: Use with caution; monitor for systemic corticosteroid effects. Increased systemic exposure to fluticasone propionate and salmeterol may occur.
Confidence: Medium

Pharmacology

πŸ”¬

Mechanism of Action

Fluticasone propionate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. It acts by binding to glucocorticoid receptors, inhibiting the release of inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) and suppressing the migration of inflammatory cells (e.g., eosinophils, mast cells, lymphocytes, macrophages, neutrophils). This reduces airway hyperresponsiveness and inflammation. Salmeterol is a long-acting beta2-adrenergic agonist (LABA). It selectively stimulates beta2-adrenergic receptors in the lungs, leading to relaxation of bronchial smooth muscle and bronchodilation. This effect is mediated by activation of adenyl cyclase, which increases intracellular cyclic AMP (cAMP) levels.
πŸ“Š

Pharmacokinetics

Absorption:

Bioavailability: Fluticasone: Low systemic bioavailability (<30% from oral inhalation). Salmeterol: Low systemic bioavailability (approximately 20-30% from oral inhalation).
Tmax: Fluticasone: 0.5-2 hours. Salmeterol: 5-10 minutes (bronchodilation onset), 1-2 hours (peak plasma concentration).
FoodEffect: Not applicable for inhaled powder.

Distribution:

Vd: Fluticasone: Approximately 318 L. Salmeterol: Approximately 15.7 L/kg.
ProteinBinding: Fluticasone: Approximately 91%. Salmeterol: Approximately 96%.
CnssPenetration: Limited for both components due to high protein binding and rapid metabolism.

Elimination:

HalfLife: Fluticasone: Approximately 7.8 hours (terminal half-life). Salmeterol: Approximately 5.5 hours (terminal half-life).
Clearance: Fluticasone: High systemic clearance (approximately 1150 mL/min). Salmeterol: High systemic clearance.
ExcretionRoute: Fluticasone: Primarily feces (as metabolites), <5% urine. Salmeterol: Primarily feces (approximately 60%), urine (approximately 25%).
Unchanged: Fluticasone: <5% in urine. Salmeterol: <5% in urine.
⏱️

Pharmacodynamics

OnsetOfAction: Salmeterol: 10-20 minutes (bronchodilation). Fluticasone: Several days to weeks for full anti-inflammatory effect.
PeakEffect: Salmeterol: 2-4 hours. Fluticasone: 1-2 weeks for maximal therapeutic benefit.
DurationOfAction: Salmeterol: Approximately 12 hours. Fluticasone: Sustained anti-inflammatory effect with twice-daily dosing.
Confidence: Medium

Safety & Warnings

⚠️

BLACK BOX WARNING

Long-acting beta2-adrenergic agonists (LABAs), such as salmeterol, increase the risk of asthma-related death. Data from a large, randomized, placebo-controlled clinical trial (SMART study) showed an increase in asthma-related deaths in patients receiving salmeterol. This finding is considered a class effect of LABAs. Therefore, fluticasone propionate and salmeterol inhalation powder is not indicated for the relief of acute bronchospasm. It should not be initiated in patients during rapidly deteriorating or life-threatening episodes of asthma or COPD. It should not be used as monotherapy for asthma. It should only be used in patients with asthma who are currently receiving but are inadequately controlled on an inhaled corticosteroid or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and, if possible, step down therapy (e.g., to an inhaled corticosteroid alone) while maintaining asthma control. Do not use fluticasone propionate and salmeterol inhalation powder more often than recommended, at higher doses than recommended, or with other LABA-containing products.
⚠️

Side Effects

Urgent Side Effects: Seek Medical Help Right Away

Although rare, some people may experience severe and potentially life-threatening side effects while taking this medication. If you notice any of the following symptoms, contact your doctor or seek medical attention immediately:

Signs of an allergic reaction: rash, hives, itching, red, swollen, blistered, or peeling skin (with or without fever), wheezing, tightness in the chest or throat, trouble breathing, swallowing, or talking, unusual hoarseness, or swelling of the mouth, face, lips, tongue, or throat
Signs of infection: fever, chills, severe sore throat, ear or sinus pain, cough, increased or changed sputum production, painful urination, mouth sores, or a wound that won't heal
Signs of high blood sugar: confusion, drowsiness, excessive thirst or hunger, frequent urination, flushing, rapid breathing, or fruity-smelling breath
Signs of low potassium levels: muscle pain or weakness, muscle cramps, or an irregular heartbeat
Signs of a weak adrenal gland: severe nausea or vomiting, extreme dizziness or fainting, muscle weakness, fatigue, mood changes, decreased appetite, or weight loss
Signs of high or low blood pressure: severe headache or dizziness, fainting, or changes in vision
Chest pain or pressure
Rapid or abnormal heartbeat
Shakiness
Feeling nervous or agitated
Changes in behavior
Vision changes, eye pain, or severe eye irritation
Burning, numbness, or tingling sensations
Choking
Voice changes
Seizures
Bone pain
Sleep disturbances
Feeling extremely tired or weak
Vaginal itching or discharge
Weight gain
Mouth irritation or sores
Redness or white patches in the mouth or throat

Important Warning: This medication can cause severe breathing problems, which may be life-threatening. If you experience difficulty breathing, worsening breathing, wheezing, or coughing after taking this medication, use a rescue inhaler and seek medical help immediately.

Other Possible Side Effects

Most people do not experience significant side effects, but some may occur. If you notice any of the following side effects or any other unusual symptoms, contact your doctor or seek medical attention if they bother you or persist:

Headache
Upset stomach or vomiting
Throat irritation
* Common cold symptoms

This is not an exhaustive list of possible side effects. If you have questions or concerns about side effects, consult your doctor. You can also report side effects to the FDA at 1-800-332-1088 or online at https://www.fda.gov/medwatch.
🚨

Seek Immediate Medical Attention If You Experience:

  • Worsening asthma or COPD symptoms (e.g., increased shortness of breath, more frequent wheezing, increased need for rescue inhaler).
  • Paradoxical bronchospasm (sudden worsening of breathing immediately after using the inhaler). Seek immediate medical attention.
  • Signs of allergic reaction (e.g., rash, hives, swelling of face/mouth, difficulty breathing). Seek immediate medical attention.
  • Signs of infection (e.g., fever, chills, increased mucus, change in mucus color).
  • Signs of systemic corticosteroid effects (e.g., easy bruising, round face, slow wound healing, mood changes, vision problems like blurred vision or eye pain).
  • Signs of cardiovascular effects (e.g., fast or irregular heartbeat, chest pain, tremors, nervousness).
πŸ“‹

Before Using This Medicine

Before Taking This Medication: Important Information to Share with Your Doctor

It is essential to inform your doctor about the following:

Any allergies you have, including allergies to this medication, its components, or other substances, such as foods or drugs. Describe the allergic reaction you experienced, including the symptoms that occurred.
If you are currently using a similar medication. If you are unsure, consult your doctor or pharmacist to determine if the medication is similar.
Any prescription or over-the-counter (OTC) medications, natural products, or vitamins you are taking that may interact with this medication. Certain medications used to treat conditions like HIV, infections, or depression may not be suitable to take with this drug. Your doctor or pharmacist can advise you on potential interactions.
If you have a milk allergy, as this may be relevant to your treatment.

Please note that this is not an exhaustive list of all potential drug interactions or health concerns related to this medication. To ensure your safety, it is crucial to:

Inform your doctor and pharmacist about all medications (prescription or OTC), natural products, and vitamins you are taking.
Discuss your health problems with your doctor and pharmacist.
Verify that it is safe to take this medication with all your other medications and health conditions.
Do not initiate, discontinue, or modify the dosage of any medication without first consulting your doctor.
⚠️

Precautions & Cautions

Important Warnings and Cautions

When taking this medication, it is essential to inform all your healthcare providers, including doctors, nurses, pharmacists, and dentists, that you are using this drug.

Effectiveness and Monitoring
It may take approximately 1 week to experience the full effect of this medication. If you have diabetes (high blood sugar), consult your doctor, as this drug may increase blood sugar levels. Immediately contact your doctor if your breathing problems worsen, your rescue inhaler becomes less effective, or you need to use it more frequently.

Dosage and Administration
Do not exceed the recommended dose or use this medication more often than prescribed. Overdose can be fatal, so it is crucial to follow your doctor's instructions. If you have any concerns, discuss them with your doctor.

Transitioning from Oral Steroids
When switching from an oral steroid to another form of steroid, you may be at risk for severe and potentially life-threatening side effects. Be aware of symptoms such as weakness, fatigue, dizziness, nausea, vomiting, confusion, or low blood sugar. If you experience any of these symptoms, contact your doctor immediately.

Stressful Situations
In the event of a severe injury, surgery, or infection, you may require additional doses of oral steroids to help your body cope with the stress. Carry a warning card indicating that you may need extra steroids in such situations.

Long-term Use and Potential Side Effects
Prolonged use of this medication may increase the risk of developing cataracts or glaucoma. Consult your doctor and schedule regular eye exams as recommended. Long-term use may also lead to osteoporosis (weak bones). Discuss your risk factors with your doctor and undergo bone density tests as advised.

Infection Risk
You may be more susceptible to infections while taking this medication. To minimize the risk, wash your hands frequently and avoid close contact with people who have infections, colds, or flu. If you have not had chickenpox or measles before, avoid exposure to these illnesses, as they can be severe or even fatal in people taking steroid medications like this one. If you have been exposed to chickenpox or measles, consult your doctor.

Special Considerations
If you are 65 or older, use this medication with caution, as you may be more prone to side effects. In children and teenagers, this medication may affect growth in some cases, so regular growth checks may be necessary. Consult your doctor to discuss any concerns.

Pregnancy and Breastfeeding
If you are pregnant, plan to become pregnant, or are breastfeeding, inform your doctor to discuss the potential benefits and risks to you and your baby.

COPD Considerations
If you have chronic obstructive pulmonary disease (COPD), you are at a higher risk of developing pneumonia. This medication may further increase this risk, so discuss your condition with your doctor.
πŸ†˜

Overdose Information

Overdose Symptoms:

  • Salmeterol overdose: Tachycardia (fast heart rate), arrhythmias, tremors, headache, palpitations, nausea, dizziness, hypokalemia (low potassium), hyperglycemia (high blood sugar).
  • Fluticasone overdose (acute): Usually no immediate symptoms. Chronic overdose: Signs of hypercorticism (Cushing's syndrome), adrenal suppression (fatigue, weakness, nausea, vomiting, low blood pressure).

What to Do:

Seek immediate medical attention or call a poison control center (1-800-222-1222). Treatment is supportive and symptomatic. Monitor cardiac function (ECG), serum potassium, and blood glucose. For chronic fluticasone overdose, gradual withdrawal of the drug may be necessary under medical supervision.

Drug Interactions

🚫

Contraindicated Interactions

  • Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, clarithromycin, cobicistat-containing products, telithromycin, nefazodone) due to increased systemic exposure to fluticasone and salmeterol, leading to increased risk of systemic corticosteroid effects and cardiovascular adverse events.
πŸ”΄

Major Interactions

  • Beta-blockers (including ophthalmic): May block the bronchodilatory effect of salmeterol and produce severe bronchospasm, especially in patients with asthma. Should generally not be used together.
  • Other long-acting beta2-adrenergic agonists (LABAs): Concomitant use is not recommended as it may lead to overdose.
  • Diuretics (loop or thiazide): May cause ECG changes and/or hypokalemia, which can be acutely worsened by beta-agonists, especially at higher doses.
  • Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs): May potentiate the cardiovascular effects of salmeterol (e.g., prolongation of QTc interval, arrhythmias). Use with extreme caution or avoid within 2 weeks of discontinuing MAOIs.
🟑

Moderate Interactions

  • Non-potassium-sparing diuretics: Increased risk of hypokalemia.
  • Xanthine derivatives (e.g., theophylline): May potentiate hypokalemia and ECG changes.
  • Corticosteroids (oral/parenteral): Increased risk of systemic corticosteroid effects.
  • Sympathomimetics: Additive cardiovascular effects.
🟒

Minor Interactions

  • Not specifically identified as minor, but general caution with other drugs affecting heart rate or potassium levels.

Monitoring

πŸ”¬

Baseline Monitoring

Pulmonary Function Tests (e.g., FEV1)

Rationale: To establish baseline lung function and assess disease severity.

Timing: Prior to initiation of therapy.

Baseline height (children/adolescents)

Rationale: To monitor for potential growth suppression due to inhaled corticosteroids.

Timing: Prior to initiation of therapy.

Ocular examination (e.g., intraocular pressure, cataracts)

Rationale: To establish baseline for potential ocular effects of corticosteroids.

Timing: Prior to initiation, especially in patients with risk factors for glaucoma or cataracts.

πŸ“Š

Routine Monitoring

Pulmonary Function Tests (e.g., FEV1)

Frequency: Periodically (e.g., every 6-12 months or as clinically indicated)

Target: Improvement from baseline, maintenance of optimal lung function.

Action Threshold: Significant decline in FEV1, worsening symptoms.

Growth (height) in pediatric patients

Frequency: Regularly (e.g., every 3-6 months)

Target: Normal growth velocity for age.

Action Threshold: Growth deceleration or stunting.

Signs/symptoms of systemic corticosteroid effects (e.g., Cushing's syndrome, adrenal suppression)

Frequency: Periodically, especially with higher doses or prolonged use

Target: Absence of signs/symptoms.

Action Threshold: Development of Cushingoid features, unexplained fatigue, weakness.

Serum potassium and glucose

Frequency: Periodically, especially in patients at risk for hypokalemia or hyperglycemia (e.g., diabetics, concomitant diuretic use)

Target: Normal ranges.

Action Threshold: Hypokalemia (<3.5 mEq/L), hyperglycemia (>126 mg/dL fasting).

Bone mineral density (BMD)

Frequency: Consider periodically in patients with risk factors for osteoporosis or prolonged high-dose use.

Target: Stable BMD.

Action Threshold: Significant bone loss.

Ocular examination (e.g., intraocular pressure, cataracts)

Frequency: Annually or as clinically indicated, especially in patients with risk factors or prolonged use.

Target: Normal intraocular pressure, absence of cataracts.

Action Threshold: Elevated IOP, cataract formation.

πŸ‘οΈ

Symptom Monitoring

  • Frequency and severity of asthma/COPD symptoms (e.g., shortness of breath, wheezing, cough, chest tightness)
  • Use of rescue inhaler (SABA)
  • Nocturnal symptoms
  • Exacerbation frequency
  • Signs of oral candidiasis (thrush)
  • Signs of paradoxical bronchospasm (immediate worsening of breathing after inhalation)
  • Signs of cardiovascular effects (e.g., palpitations, tremor, chest pain)
  • Signs of systemic corticosteroid effects (e.g., easy bruising, moon face, weight gain, mood changes)

Special Patient Groups

🀰

Pregnancy

Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown teratogenic effects with high doses of fluticasone and salmeterol.

Trimester-Specific Risks:

First Trimester: Potential for teratogenicity, though systemic exposure is low with inhaled route.
Second Trimester: Potential for fetal growth restriction or adrenal suppression with high doses.
Third Trimester: Potential for fetal adrenal suppression, particularly if mother receives high doses close to delivery. Neonates should be monitored for hypoadrenalism.
🀱

Lactation

L3 (Moderate risk). It is not known whether fluticasone or salmeterol are excreted in human milk. However, other corticosteroids and beta2-agonists are excreted. Caution should be exercised when administered to a nursing mother. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition.

Infant Risk: Potential for systemic effects in the infant (e.g., growth suppression, adrenal suppression, cardiovascular effects) if significant amounts are transferred. Monitor breastfed infants for adverse effects.
πŸ‘Ά

Pediatric Use

Wixela Inhub 250/50 mcg is approved for asthma in patients 12 years of age and older. For children 4-11 years, lower strengths of fluticasone/salmeterol (e.g., 100/50 mcg) may be used. Monitor growth velocity in pediatric patients receiving inhaled corticosteroids, as growth suppression can occur. The lowest effective dose should be used.

πŸ‘΄

Geriatric Use

No dosage adjustment is generally required. However, elderly patients may be more susceptible to the cardiovascular effects of salmeterol (e.g., arrhythmias, tremors) and systemic corticosteroid effects (e.g., osteoporosis, cataracts, glaucoma). Monitor for comorbidities and potential drug interactions.

Clinical Information

πŸ’Ž

Clinical Pearls

  • Emphasize that this is a maintenance medication, not a rescue inhaler. Patients must have a SABA for acute symptoms.
  • Proper inhaler technique is crucial for efficacy. Demonstrate and have the patient demonstrate back.
  • Rinsing the mouth after each dose is essential to prevent oral candidiasis (thrush).
  • Warn patients about the black box warning regarding LABA use in asthma and the importance of not using additional LABA-containing products.
  • Monitor for signs of systemic corticosteroid effects, especially with higher doses or prolonged use, and in patients with risk factors.
  • Counsel patients on the importance of adherence, even when feeling well, to maintain asthma/COPD control.
  • Be aware of potential drug interactions, especially with strong CYP3A4 inhibitors, beta-blockers, and drugs that prolong the QTc interval.
πŸ”„

Alternative Therapies

  • Inhaled Corticosteroid (ICS) monotherapy (e.g., fluticasone propionate, budesonide, mometasone)
  • Long-Acting Muscarinic Antagonist (LAMA) monotherapy (e.g., tiotropium, umeclidinium) for COPD
  • Short-Acting Beta2-Adrenergic Agonist (SABA) for rescue (e.g., albuterol, levalbuterol)
  • Oral corticosteroids (for severe exacerbations or refractory disease)
  • Leukotriene receptor antagonists (e.g., montelukast)
  • Phosphodiesterase-4 inhibitors (e.g., roflumilast) for severe COPD
  • Biologic therapies (e.g., omalizumab, mepolizumab, benralizumab, dupilumab) for severe asthma
πŸ’°

Cost & Coverage

Average Cost: Approximately $150 - $300 per 60-dose inhaler
Generic Available: Yes
Insurance Coverage: Tier 2 or Tier 3 (preferred or non-preferred brand/generic)
πŸ“š

General Drug Facts

If your symptoms or health issues persist or worsen, it's essential to contact your doctor for further guidance. To ensure your safety, never share your medication with others or take someone else's medication. Some medications may come with an additional patient information leaflet, so be sure to check with your pharmacist for more information. If you have any questions or concerns about your medication, don't hesitate to reach out to your doctor, nurse, pharmacist, or other healthcare provider. In the event of a suspected overdose, immediately call your local poison control center or seek medical attention. When seeking help, be prepared to provide details about the medication taken, the amount, and the time it happened.